Literature DB >> 8199118

Genetic and clinical determinants for the T cell mediated immune response against the cornea specific protein BCP 54.

M J Jager1, H J Völker-Dieben, L de Waal, F G Kok, L Broersma, R van der Gaag.   

Abstract

T cell mediated immune responses against the cornea specific protein BCP 54 have been observed in patients with uveitis, Fuchs' heterochromic cyclitis, and corneal disease. The pathophysiological role of this anti-BCP 54 response in corneal disease is not known. In order to ascertain whether the presence of such an immune response is related to the corneal disease itself or related to genetic influences, the anti-BCP 54 response was determined in 104 patients with severe corneal disease, using a monocyte migration inhibition assay. The results were compared with the presence of a variety of ocular parameters as well as with the distribution of HLA antigens in these patients. While only 7% of healthy controls responded to BCP 54, 37% of the patients showed a positive response (p = 0.002); in particular, patients with previous graft rejection, non-herpetic keratitis, and bullous keratopathy reacted against BCP 54. No relation with known risk factors for corneal transplantation, such as corneal neovascularisation, was observed. No significant association with the presence of any of the HLA antigens was observed. It was concluded that the main inducer of an anti-BCP 54 response is corneal disease itself, and that the presence of corneal disease is able to break the immunological privilege typical of normal corneas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8199118      PMCID: PMC504767          DOI: 10.1136/bjo.78.4.298

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  14 in total

Review 1.  Anterior chamber associated immune deviation: the privilege of immunity in the eye.

Authors:  J W Streilein
Journal:  Surv Ophthalmol       Date:  1990 Jul-Aug       Impact factor: 6.048

2.  The influence of donor-recipient sensitization on corneal grafts.

Authors:  A E MAUMENEE
Journal:  Am J Ophthalmol       Date:  1951-05       Impact factor: 5.258

3.  Evidence for an HLA-DR4-associated immune-response gene for Mycobacterium tuberculosis. A clue to the pathogenesis of rheumatoid arthritis?

Authors:  T H Ottenhoff; P Torres; J T de las Aguas; R Fernandez; W van Eden; R R de Vries; J L Stanford
Journal:  Lancet       Date:  1986-08-09       Impact factor: 79.321

Review 4.  Immune privilege and immune regulation in the eye.

Authors:  J Y Niederkorn
Journal:  Adv Immunol       Date:  1990       Impact factor: 3.543

5.  Immunity to a corneal antigen in Fuchs' heterochromic cyclitis patients.

Authors:  R van der Gaag; L Broersma; A Rothova; S Baarsma; A Kijlstra
Journal:  Invest Ophthalmol Vis Sci       Date:  1989-03       Impact factor: 4.799

6.  Simultaneous detection of two cell populations by two-colour fluorescence and application to the recognition of B-cell determinants.

Authors:  J J van Rood; A van Leeuwen; J S Ploem
Journal:  Nature       Date:  1976-08-26       Impact factor: 49.962

7.  Tissue and species specificity of BCP 54, the major soluble protein of bovine cornea.

Authors:  B Silverman; R J Alexander; W L Henley
Journal:  Exp Eye Res       Date:  1981-07       Impact factor: 3.467

8.  T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination.

Authors:  S Zamvil; P Nelson; J Trotter; D Mitchell; R Knobler; R Fritz; L Steinman
Journal:  Nature       Date:  1985 Sep 26-Oct 2       Impact factor: 49.962

9.  Autoimmunity against corneal antigens. I. Isolation of a soluble 54 Kd corneal epithelium antigen.

Authors:  P J Kruit; R van der Gaag; L Broersma; A Kijlstra
Journal:  Curr Eye Res       Date:  1986-04       Impact factor: 2.424

10.  HLA-DR3- and HLA-DR7-restricted T-cell hyporesponsiveness to gluten antigen: a clue to the aetiology of coeliac disease?

Authors:  H Scott; H Hirschberg; E Thorsby
Journal:  Scand J Immunol       Date:  1983-08       Impact factor: 3.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.